Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesCardiologyBlue Cross Blue Shield MA TTE Coverage Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 115

    Transthoracic Echocardiography (TTE) — Medical Necessity and Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 115 alerts

    Get alerted when Policy 115 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity policy for transthoracic echocardiography (including stress echocardiography) for commercial members of Blue Cross Blue Shield Massachusetts; describes indications, frequency guidance, and when TTE is considered medically necessary.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyTransthoracic Echocardiography (TTE) — Medical Necessity and Coverage Criteria
    Policy CodePolicy 115
    Change TypeNew policyminor billing link update
    Effective DateOct 14, 2024
    Last ReviewOct 1, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for inpatient TTE services and document medical necessity per policy criteria.
    SourceLink
    POLICY UPDATE CHANGES

    New medical policy describing medically necessary and not medically necessary indications; Effective 10/14/2024.

    Updated link to Billing and Coding Article A56781.

    ≈15Included CPT codes
    >2 segsContrast indication
    1/yrAnnual limit for stable valvular disease
    InpatientPrecertification requirement
    Not covered3D echo alone
    10/1/2019Last revision

    Coverage and Medical Necessity Criteria

    inv-01: Medically necessary indications

    TTE is considered MEDICALLY NECESSARY for the following indications (selection of preserved document sections):

    General cardiac evaluation: When history, physical examination, or routine laboratory tests suggest or cannot eliminate cardiac disease (e.g., dyspnea, edema with suspected elevated central venous pressure), TTE is the preferred initial diagnostic test.
    Hypertensive heart disease: Evaluation of cardiac effects of systemic hypertension, including assessment for left ventricular hypertrophy or mass to guide therapy in young or borderline hypertensive individuals.
    Acute myocardial infarction and ischemia: Evaluation of regional wall motion, right ventricular ischemia/infarction, diagnosis and complications of acute MI (mural thrombi, papillary muscle dysfunction/rupture, septal defects, aneurysm) and assessment of chest pain when ECG/laboratory markers are nondiagnostic.

    Repeat TTE frequency after acute infarction should be documented and dictated by clinical course.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyTransthoracic Echocardiography (TTE) — Medical Necessity and Coverage Criteria
    Policy CodePolicy 115
    Change TypeNew policyminor billing link update
    Effective DateOct 14, 2024
    Last ReviewOct 1, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for inpatient TTE services and document medical necessity per policy criteria.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure and Billing CodesProvider Requirements, Prior Authorization, and DocumentationClinical BackgroundDefinitions and Key Terms
    Cardiotoxic exposure monitoring: Baseline complete TTE prior to administration of cardiotoxic agents with repeat studies as clinically indicated (tests performed bimonthly during chemotherapy and at approximately 6 months following therapy are generally appropriate).
    Transplant and rejection monitoring: Baseline and serial TTE for donor selection, recipient matching, and monitoring allograft function; typically weekly for the first 4–8 weeks post-transplant and approximately twice yearly in stable chronic recipients.
    Valvular disease: Primary choice for evaluation of native valvular pathology and hemodynamic effect; Doppler may be required.

    It is not medically necessary to repeat these examinations more than once per year when clinical status is stable.

    Prosthetic valves: Post-implant baseline TTE to establish structural and hemodynamic profile with reassessment at 3–6 months; thereafter reassessment for suspected dysfunction, thrombosis, or change in clinical status.
    Endocarditis: Diagnostic evaluation of suspected infective endocarditis and its complications or sequelae; examination frequency dictated by clinical course.
    Pericardial disease: Detection and quantification of pericardial effusion, characterization of hemodynamic consequences, diagnosis of constrictive versus restrictive disease, and as an adjunct during pericardial fluid removal.
    Great vessel abnormalities: Evaluation of acute or chronic aortic pathology, routine yearly evaluation for severe aortic stenosis/regurgitation when it informs care, assessment of ascending aortic dilation, and evaluation of pulmonary artery segments and vena cavae abnormalities.
    Congenital heart disease: Diagnosis and serial noninvasive assessment of most congenital heart diseases with Doppler; when stable, more than annual assessment requires documentation of medical necessity.
    Suspected cardiac thrombi/embolic sources: Evaluation for cardiovascular sources of embolic events (PFO/ASD, atrial/ventricular thrombus, intracardiac tumor) in patients with abrupt occlusion of major arteries or neurological events without other cause.
    Cardiac tumors: Diagnosis and serial monitoring of cardiac tumors and masses.
    Critically ill and trauma patients: Evaluation of suspected aortic or central pulmonary pathology, cardiac contusion, pericardial effusion, and assessment of volume status; frequency dictated by clinical circumstances.
    Arrhythmias and palpitations: Evaluate cardiac function in patients with arrhythmias when there is evidence of heart disease (e.g., atrial fibrillation/flutter).

    inv-02: Medically Necessary Indications

    Covered when specified clinical indications or study types meet medical necessity criteria

    Acute/critical indications: TTE is medically necessary for suspected aortic or central pulmonary pathology, cardiac contusion, pericardial effusion, and assessment of volume status in critically ill or trauma patients.
    Arrhythmia-related evaluation: TTE is appropriate to evaluate cardiac function when arrhythmias occur and there is evidence of heart disease (e.g., atrial fibrillation or flutter).
    Syncope: TTE is medically necessary in the initial evaluation of syncope when other findings suggest valvular heart disease or obstructive cardiomyopathy.
    Pulmonary / RV assessment: TTE to assess right ventricular size/function and to quantify pulmonary hypertension using Doppler in unexplained pulmonary hypertension or when right‑sided sources of emboli are suspected.
    Contrast echocardiography: Contrast is medically necessary when a noncontrast study is inadequate to delineate left ventricular endocardial borders and more than two (2) contiguous LV segments are not visualized, and LV function information is essential to management.>2 contiguous segments not visualized
    Follow-up/limited studies: Limited or follow-up studies are medically necessary for defined situations (e.g., post‑operative pericardial effusion monitoring, serial LV function during chemotherapy, sequential transmitral velocity in mitral stenosis, estimation of pulmonary artery systolic pressure).
    Doppler and color flow mapping: Spectral Doppler and color flow mapping may be medically necessary when they contribute significant diagnostic, prognostic, or treatment information (e.g., murmurs, valvular disease, shunts, post‑MI complications, cardiomyopathy).
    Stress echocardiography may be medically necessary in suspected or known ischemic heart disease and related indications (post‑MI prognosis, detect CAD, evaluate extent of ischemia after revascularization, pre‑operative high‑risk assessment, evaluate cardiomyopathy or transplant rejection, exercise hemodynamics for valvular disease) when it will contribute clinically relevant information.

    Multiple stress modalities for the same event are covered only if the preceding test was inconclusive or uninterpretable.

    3D echocardiography performed in conjunction with TTE is medically necessary for specific indications (e.g., pre‑operative mitral valve repair planning; monitoring mitral valve area in moderate–severe mitral stenosis). 3D echocardiography performed alone is not medically necessary due to unproven impact on clinical outcomes.

    inv-03: Not Medically Necessary / Not Covered

    Not covered / Not medically necessary

    Screening: Echocardiography performed for screening purposes (including for risk factors or family history) is not covered.
    Routine re-evaluation without change: Routine (yearly) re-evaluation of listed conditions without change in clinical status (examples: mitral valve prolapse with no/mild MR and no change; asymptomatic repaired ASD/VSD/PDA >1 year post‑repair; mild native aortic stenosis or mild–moderate mitral stenosis with no change; prosthetic valve with no suspicion of dysfunction and no change; mild regurgitation with no change; stable heart failure; hypertrophic cardiomyopathy with no change) is not medically necessary.
    Isolated APC/VPC or palpitations without arrhythmia: Palpitations without documented arrhythmia, or isolated atrial premature complexes (APC) or ventricular premature complexes (VPC) without other evidence of heart disease are not covered indications.
    Stress testing redundance: Stress tests by multiple modalities for the same clinical event are covered only if the preceding test was inconclusive or uninterpretable; otherwise multiple modality testing is not covered.

    inv-04: General medical necessity requirement

    Covered when ALL of the following are met

    Main coverage condition: The specific medical necessity criteria in this policy and in Billing and Coding Article A56781 are met for the submitted CPT/HCPCS code and accompanying ICD‑10 diagnosis.

    Applies to Commercial Members (Managed Care HMO/POS, PPO, and Indemnity).

    Repeating transthoracic echocardiography (TTE) more than once per year for stable native valvular disease is not medically necessary unless there is documentation of a change in the patient’s clinical status or the plan of care requires more frequent assessment (for example, when imminent valvular surgery is being considered).

    Echocardiography performed for screening purposes is not covered. Routine annual re-evaluation in stable or asymptomatic patients for the listed conditions (for example, mitral valve prolapse with no or mild regurgitation and no change in status; asymptomatic repaired ASD/VSD/PDA >1 year after correction; mild native aortic stenosis or mild–moderate mitral stenosis with no change; prosthetic valve with no suspicion of dysfunction and no change) is not medically necessary and therefore excluded.

    The presence of a CPT/HCPCS code on the policy lists does not by itself guarantee coverage or reimbursement. Coverage requires that the service meet the medical necessity criteria described in this policy and that member contract benefits apply; inclusion or exclusion of a code is informational and does not determine coverage.

    Three-dimensional (3D) echocardiography performed alone is considered not medically necessary because, although it may improve volumetric calculations compared with 2D imaging, its impact on clinical outcomes is not proven. 3D echocardiography may be medically necessary when performed with TTE for specific indications (for example, pre‑operative mitral valve repair planning or monitoring mitral valve area in moderate–severe mitral stenosis).

    If the documented clinical indications do not meet the medical necessity criteria in this policy (and the referenced Billing & Coding guidance), the CPT/HCPCS codes listed will not be covered. Providers should cross‑reference the policy with the Billing & Coding Article A56781 and report services using current industry codes and modifiers as applicable.

    Procedure and Billing Codes

    Included Procedure Codesmixed
    93306Echocardiography, transthoracic, real-time with image documentation (2D), includes m- mode recording; when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
    93307Echocardiography, transthoracic, real-time with image documentation (2D) , includes m- mode recording, when performed, complete, without spectral or color doppler echocardiography
    93308Echocardiography, transthoracic, real-time with image documentation (2D) , includes m- mode_recordingwhen performed_follow-up or limited study
    C8923Transthoracic echocardiography with contrast; or without contrast followed by with contrast; real-time with image documentation (2D);, includes m-mode recording; when performed_complete,_without spectral or color doppler echocardiography
    C8924Transthoracic echocardiography with contrast; or without contrast followed by with performed,follow-up or limited study
    C8929Transthoracic echocardiography with contrast; or without contrast followed by with contrast; real-time with image documentation (2D), includes m-mode recording; when performed; complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
    Covered CPT/HCPCS Codes (general TTE)mixedCovered
    93306Echocardiography, transthoracic, real-time with image documentation (2D), includes m- mode recording; when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
    93307Echocardiography, transthoracic, real-time with image documentation (2D) , includes m- mode recording, when performed, complete, without spectral or color doppler echocardiography
    93308Echocardiography, transthoracic, real-time with image documentation (2D) , includes m- mode_recordingwhen performed_follow-up or limited study
    C8923Transthoracic echocardiography with contrast; or without contrast followed by with contrast; real-time with image documentation (2D);, includes m-mode recording; when performed_complete,_without spectral or color doppler echocardiography
    C8924Transthoracic echocardiography with contrast; or without contrast followed by with performed,follow-up or limited study
    C8929Transthoracic echocardiography with contrast; or without contrast followed by with contrast; real-time with image documentation (2D), includes m-mode recording; when performed; complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
    Covered CPT/HCPCS Codes (congenital anomalies)mixedCovered
    93303Transthoracic echocardiography for congenital cardiac anomalies;_complete.
    93304Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study.
    C8921Transthoracic echocardiography with contrast; or without contrast followed by with contrast_for congenital cardiac anomalies;_complete_.
    C8922Transthoracic echocardiography with contrast; or without contrast followed by with contrast,_for congenital cardiac anomalies; follow-up or limited study
    Covered CPT/HCPCS Codes (stress echocardiography)mixedCovered
    93350Echocardiography, transthoracic, real-time with image documentation (2D), includes m- mode recording; when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise andlor pharmacologically induced stress, with interpretation and report;
    93351Echocardiography, transthoracic, real-time with image documentation (2D), includes m- mode recording; when performed, during rest and cardiovascular stress test using treadmill; bicycle exercise andlor pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional.
    93352Use of echocardiographic contrast agent during stress echocardiography (list separately in addition to code for primary procedure).
    C8928Transthoracic echocardiography with contrast; or without contrast followed by with contrast, real-time with image documentation (2D) , includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill; bicycle exercise andlor_pharmacologically _induced stress_with _interpretation and report.
    C8930Transthoracic echocardiography, with contrast; or without contrast followed by with contrast; real-time with image documentation (2D) , includes m-mode recording; when performed, during rest and cardiovascular stress test using treadmill; bicycle exercise andlor pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring_with physician supervision
    3D rendering CPT codes cross-linked to TTE CPTsCPT
    763763D rendering with interpretation and reporting of computed tomography; magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation.
    763773D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging; ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing.
    Contrast use threshold
    Contrast use thresholdContrast is medically necessary when noncontrast study inadequately delineates LV endocardial borders and more than two (2) contiguous left ventricular segments are not visualized.
    Clinical requirementLV function information must be essential to patient management for contrast to be indicated.
    Trigger for useApplied when a conventional (noncontrast) study fails to provide adequate and critically needed information on left ventricular function.
    3D rendering linkage
    3D rendering linkage (no postprocessing workstation)CPT 76376 crosswalks to TTE CPT 93303 (3D rendering without requiring image postprocessing on an independent workstation).
    3D rendering linkage (requires postprocessing)CPT 76377 crosswalks to TTE CPT 93304 (3D rendering requiring image postprocessing).
    Context3D rendering codes are mapped to congenital TTE CPTs in the policy's coding crosswalk.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required for Inpatient

    This policy applies to Commercial Members (Managed Care HMO/POS, PPO, and Indemnity). Prior authorization/precertification is required for inpatient transthoracic echocardiography (TTE) services. For outpatient services, prior authorization requirements vary by product; Commercial Managed Care (HMO and POS) typically does not require outpatient prior authorization, while Commercial PPO and Indemnity may have different requirements — verify member contract and product-specific rules.

    • Applies to Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity.
    • Preauthorization/precertification IS REQUIRED for all products if the procedure is performed inpatient.
    • Outpatient prior authorization requirements vary by product — confirm per member contract.
    Documentation Required

    Doppler Documentation

    Doppler (spectral Doppler and color flow-velocity mapping) is considered medically necessary when it would contribute significant information to diagnosis, prognosis, or treatment (for example, evaluation of murmurs, valvular disease, shunts, congenital heart disease, post-MI complications, or cardiomyopathy). Because Doppler is an inherent part of a comprehensive echocardiographic evaluation, reports and medical records must document the use of Doppler techniques when clinically indicated. If the report fails to document Doppler use or the medical record does not support clinical necessity, the Doppler portion may be considered NOT MEDICALLY NECESSARY.

    • Doppler should be used and documented when it can affect diagnosis or management (e.g., valve assessment, pulmonary pressure estimation, diastolic function).
    • Failure to document use of Doppler techniques or clinical necessity may lead to the Doppler portion being deemed NOT MEDICALLY NECESSARY.
    Denial Risk

    Denial Risk When Medical Necessity Criteria Not Met

    Coverage for the procedures and CPT/HCPCS codes listed in this policy requires that the above medical necessity criteria be documented in the medical record. Absence of documentation meeting medical necessity criteria may result in claim denials or portions of the study being denied as not medically necessary.

    • Medical necessity must be documented in the medical record for the covered codes.
    • Lack of documented medical necessity may lead to denial of payment.
    Documentation Required

    Document Frequency After Acute MI

    After an acute myocardial infarction, the timing and frequency of repeat TTE are determined by the patient’s acute clinical course. The medical record must document the clinical rationale and necessity for the frequency of repeated TTE assessments.

    • Repeat TTE frequency post-acute MI should be dictated by clinical course and clearly documented in the medical record.
    Documentation Required

    Transplant Monitoring Documentation

    For cardiac transplant recipients, serial TTE monitoring is typically performed weekly during the first 4–8 weeks post-transplant with decreasing frequency thereafter. In chronic transplant recipients without acute rejection, approximately two TTEs per year are typical. Serial evaluations should be performed at transplant centers by examiners experienced in managing cardiac allograft recipients.

    • Typical schedule: weekly for first 4–8 weeks post-transplant, then reduced frequency; ~2 TTEs/year in stable chronic recipients.
    • Examinations should be performed by experienced examiners at transplant centers.
    Documentation Required

    Study Report and Clinical Necessity

    A complete echocardiographic study requires review and measurement of images by a physician and preparation of a written report that documents findings, data supporting conclusions, and clinical necessity. Limited or follow-up studies must indicate the specific focused indication. For follow-up or limited studies, document why a complete study is not required and the clinical question being addressed.

    • Physician review of images, measurements, analysis, interpretation, and a written report are required for a complete study.
    • When performing limited or follow-up studies, document the specific indication (e.g., assess effusion progression, serial LV function during chemotherapy).
    • Studies performed with limited-capability scanners must still meet standards and include a permanent record; otherwise they may be considered not medically necessary.

    Clinical Background

    Transthoracic echocardiography (TTE) is a noninvasive imaging modality performed via the chest wall to evaluate cardiac structure and function. It is the preferred initial diagnostic test when history, physical examination, or routine tests suggest or cannot exclude cardiac disease, and it has established roles in assessing valvular disease, endocardial and myocardial abnormalities, pericardial disease, ischemia/acute myocardial infarction, transplant monitoring, congenital heart disease, and suspected cardiac sources of embolism.

    Definitions and Key Terms

    TTE (Transthoracic Echocardiography)
    DefinitionTransthoracic echocardiography (TTE) is noninvasive echocardiographic imaging performed via the chest wall to assess cardiac structure and function.
    Inclusion of DopplerTTE includes Doppler techniques (spectral and color flow) when clinically indicated to assess blood flow velocity and hemodynamics.
    Typical rolePreferred initial diagnostic test when history, physical exam, or routine tests suggest or cannot eliminate cardiac disease.
    Complete study
    Complete study definitionA full evaluation of all aspects of the heart including cardiac chambers, valves, blood flow, and great vessels with images reviewed, measured, analyzed and interpreted by the physician; a report is prepared for the patient's record.
    ComponentsRecorded images, physician review with measurements and analysis, and a written report sufficient to support conclusions.
    When limited/follow-up usedA less-than-complete exam may be performed for evaluation of a specific cardiac problem or region and reported as a follow-up or limited study when clinically appropriate.
    Contrast echocardiography indication
    Indication for contrastUse contrast to delineate left ventricular endocardial borders when a noncontrast study is inadequate and more than two (2) contiguous LV segments are not visualized.
    PurposeTo obtain LV function information essential to patient management when noncontrast images are suboptimal.
    PreconditionContrast is indicated only after a conventional study has failed to provide adequate and critically needed information on LV function.
    Doppler flow evaluation
    DefinitionDoppler flow evaluation uses frequency changes of reflected ultrasound to measure blood flow velocity.
    Clinical purposesUsed to identify valvular stenosis or regurgitation, estimate cardiac output and intracardiac pressures, and identify intracardiac shunts.
    When requiredMay be medically necessary as part of TTE when it contributes significant diagnostic, prognostic, or therapeutic information (e.g., murmurs, valvular disease, shunts, cardiomyopathy).
    Valid echocardiographic service
    Definition of valid serviceA valid echocardiographic service is performed for an accepted clinical indication by a properly trained examiner and must include a permanent record of findings, sufficient data to support conclusions, an appropriate interpretation, and a written report.
    Examiner requirementMust be performed by a properly trained examiner (meets standards for a complete diagnostic echocardiographic examination).
    Documentation requirementPermanent record of images and a physician-prepared written report are required to meet standards.